Señales en vivo de RVU.WA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 may 2024 @ 11:00):

Stats
Volumen de hoy	2 291.00
Volumen promedio	4 242.00
Capitalización de mercado	1.15B
EPS	PLN-0.800 ( 2023-11-29 )
Last Dividend	PLN0 ( N/A )
Next Dividend	PLN0 ( N/A )
P/E	-12.46
ATR14	PLN0.151 (0.30%)

Volumen Correlación

Largo: 0.01 (neutral)

Corto: 0.09 (neutral)

Signal:(41.636) Neutral

Ryvu Therapeutics S.A. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ryvu Therapeutics S.A. Correlación - Moneda/Commodity

0.82
( strong )

0.75
( moderate )

0.69
( moderate )

-0.33
( neutral )

0.69
( moderate )

-0.10
( neutral )

Ryvu Therapeutics S.A. Finanzas

Annual	2023
Ingresos:	PLN46.86M
Beneficio Bruto:	PLN-113.44M (-242.09 %)
EPS:	PLN-4.02

FY	2023
Ingresos:	PLN46.86M
Beneficio Bruto:	PLN-113.44M (-242.09 %)
EPS:	PLN-4.02

FY	2022
Ingresos:	PLN38.80M
Beneficio Bruto:	PLN21.40M (55.14 %)
EPS:	PLN-4.57

FY	2021
Ingresos:	PLN11.19M
Beneficio Bruto:	PLN-2.54M (-22.69 %)
EPS:	PLN-0.965

Financial Reports:

No articles found.

Ryvu Therapeutics S.A.

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.